FDA bans another Ranbaxy plant

Share this article:

Ranbaxy's US woes continue. The FDA announced Friday that it has now banned drugs from the firm's Toansa, India, facility. As noted by Bloomberg, this is now the fourth Ranbaxy manufacturing site that's a no-go in terms of providing products to the US. The latest reason: FDA inspectors found workers manipulated testing results so that failed drugs passed testing requirements.

The FDA ban's reach is pretty substantial because it bars fully manufactured drugs from entering the US, in addition to preventing US facilities from incorporating active ingredients from the facility into US-produced items.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions